CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
VISITING CHICAGO? JOIN US IN RECOGNIZING OUR 2018 GIANTS OF CANCER CARE® ON MAY 31st AND VISIT BOOTH 2073 JUNE 2nd-4th!
<< View More Conferences
2016 ASH Annual Meeting and Exposition
Oncology Conference Multimedia
View more videos >>
Dr. Chaudhary on Remaining Challenges With CAR T-Cell Therapy
Dr. Goy on the Role of MRD in Mantle Cell Lymphoma
Dr. Kelly on Racial Disparities in Multiple Myeloma
Oncology Conference Articles
Expert Discusses Key Daratumumab Data Presented at ASH
Saad Z. Usmani, MD, discusses the latest developments with daratumumab in the treatment of patients with multiple myeloma, many of which were presented at the recent 2016 ASH Annual Meeting.
Expert Touts Value of Lenalidomide Maintenance in Myeloma
Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.
Transplant Remains Pivotal in Myeloma, Other Hematologic Cancers
The use of stem cell transplantation has changed over the last few years, with the emergence of novel therapies and treatment strategies. But even with the FDA approvals of new agents for multiple myeloma and select lymphomas, transplant remains to be a curative and reliable strategy.
Expert Explains WHO Classification Refinements in Hematologic Malignancies
Changes are underway in the field of hematologic malignancies, as the World Health Organization is publishing a revised classification of tumors of hematopoietic and lymphoid tissues—slated to be released in early 2017.
Myeloma Expert Highlights Practice-Changing ASH Findings
The landscape of multiple myeloma continues to shift with more drug approvals, but pivotal results out of the 2016 ASH Annual Meeting will likely alter it even further.
Lenalidomide Shows Activity in Low-Risk MDS
Results from the randomized phase II HOVON89 trial showed that nearly 40% of patients with low intermediate-1 risk myelodysplastic syndrome who were refractory to erythropoietin and granulocyte-colony stimulating factor experienced hematologic improvement with erythroid response after being treated with lenalidomide monotherapy.
Venetoclax Active in Heavily Treated Multiple Myeloma
The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma.
Benefits of Daratumumab Triplets in Myeloma Sustained With Longer Follow-Up
The benefits of 2 FDA-approved daratumumab–based triplet regimens were sustained in long-term data from 2 pivotal phase III studies presented at the 2016 ASH Annual Meeting.
Entospletinib Shows Modest Activity in Mantle Cell Lymphoma
Entospletinib was well tolerated and demonstrated modest activity in patients with relapsed or refractory mantle cell lymphoma.
High Rates of Symptoms, Impairment, With Myeloproliferative Neoplasms
Patients with myeloproliferative disorders have a high symptom burden that significantly affects emotional status, quality of life, and functional ability.
Ruxolitinib Demonstrates Consistent Survival Benefit in Myelofibrosis
Patients with intermediate/high-risk myelofibrosis had improved survival when treated long term with the Janus kinase inhibitor ruxolitinib.
Novel Agent Slows High-Risk Myelofibrosis in Initial Trial
A third of patients with previously treated, high- and intermediate-risk myelofibrosis had objective responses to the investigational Second mitochondria-derived activator of caspases mimetic LCL161.
Gene Expression Studies Offer Insight Into Myeloma Regimen's Efficacy
An analysis of c-MYC expression in relapsed myeloma identified subgroups of patients with improved response to the combination of an immunomodulator and a proteasome inhibitor.
Dual Transplant Prevails in Patients With Newly Diagnosed Myeloma
Patients with newly diagnosed multiple myeloma had significant improvement in progression-free survival when treated with dual versus single autologous stem-cell transplant.
Expanded Access Data Confirm Safety, Efficacy of Ruxolitinib in Myelofibrosis
Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib (Jakafi) in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.
Addition of Daratumumab Triples Increase in MRD Conversion in Relapsed Myeloma
The addition of daratumumab to standard-of-care regimens tripled the increase in conversion to negative minimal residual disease status in the treatment of patients with relapsed/refractory multiple myeloma.
Elotuzumab Triplet Yields High Response Rate in High-Risk Smoldering MM
The combination of elotuzumab, lenalidomide, and dexamethasone has excellent activity and is well-tolerated in the treatment of high-risk smoldering multiple myeloma (SMM), providing hope that it can delay or even halt progression to MM.
More Randomized Data Support Pacritinib Efficacy in Myelofibrosis
Patients with myelofibrosis and thrombocytopenia had significantly greater reductions in spleen volume and symptoms when treated with the multikinase inhibitor pacritinib, compared with the best available therapy.
JCAR017 Shows Promising Activity, Mild Toxicity in CD19+ Lymphoma
The CD19-directed CAR T-cell therapy JCAR017 demonstrated a 60% complete response rate in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma.
Multiple Myeloma Transplant Trial Shows No Extra Benefit with Additions to Standard Therapy
According to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.
Nivolumab-Brentuximab Vedotin Combo Active and Safe in Relapsed Hodgkin Lymphoma
Early data from a phase I/II study suggest that the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) may be an active and well-tolerated outpatient regimen in patients with relapsed/refractory classical Hodgkin lymphoma after failure of standard frontline chemotherapy.
High Response Rate With Venetoclax in Relapsed/Refractory CLL
Two thirds of patients with chronic lymphocytic leukemia (CLL) that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax, results of a small open-label trial showed.
KTE-C19 Leads to High Response Rates in Refractory NHL
Almost 80% of patients with treatment-refractory non-Hodgkin lymphoma had objective responses following treatment with KTE-C19, a chimeric antigen receptor T-cell therapy targeting CD19.
Ibrutinib Shows Promise in Treating GVHD After Stem Cell Transplant
An FDA-approved blood cancer drug has demonstrated encouraging findings, including an overall response rate of 67%, in treatment of patients with chronic graft-versus-host-disease that was not resolved by corticosteroids.
Subcutaneous Daratumumab Safe, Effective in Myeloma
Subcutaneous delivery of daratumumab was well tolerated with comparable efficacy to the FDA-approved intravenous dose in patients with relapsed/refractory multiple myeloma.
Venetoclax Highly Effective With Bortezomib/Dexamethasone for Multiple Myeloma
Adding venetoclax to bortezomib and dexamethasone showed very promising efficacy and acceptable safety for patients with relapsed/refractory multiple myeloma.
Selinexor Active in Heavily Pretreated Myeloma
Selinexor, in combination with dexamethasone, induced a response rate of 20.5% (n = 16) among 78 heavily pretreated patients with relapsed/refractory multiple myeloma, according to results from the phase IIb STORM trial presented at the 2016 ASH Annual Meeting.
KTE-C19 Response Rates Spark FDA Submission for Aggressive Lymphomas
Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma.
Early Study Signals Promising Role for Venetoclax in Treatment of Relapsed CLL
Adding the oral BCL-2 inhibitor venetoclax (Venclexta) to obinutuzumab (Gazyva) and ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia is safe and is demonstrating encouraging signs of efficacy.
Ibrutinib Regimen Induces 100% Induction Response in CLL
An induction regimen of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) after bendamustine debulking induced a 100% response rate in patients with chronic lymphocytic leukemia.
BGB-3111 Response Rate Nears 100% in CLL/SLL
Treatment with the BTK inhibitor BGB-3111 had an objective response rate of 96% for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.
Acalabrutinib Safe, Effective in Ibrutinib-Intolerant CLL/SLL
The investigational Bruton tyrosine kinase inhibitor acalabrutinib was shown to be well-tolerated in patients with chronic lymphocytic leukemia and small lymphocytic leukemia who display intolerance to ibrutinib (Imbruvica).
TGR-1202/Ibrutinib Combo Feasible, Highly Active for CLL/MCL
The combination of the PI3 kinase inhibitor TGR-1202 and ibrutinib demonstrated a high response rate without dose-limiting toxicities for patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.
Frontline Obinutuzumab Significantly Improves PFS in Follicular Lymphoma
Combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34% versus rituximab plus chemotherapy in patients with follicular lymphoma, according to findings from the phase III GALLIUM study.
Pembrolizumab Combo Highly Effective for Heavily Pretreated Myeloma
Treatment with the combination of pembrolizumab, pomalidomide, and dexamethasone demonstrated promising durable efficacy and a tolerable safety profile for patients with relapsed/refractory multiple myeloma.
After 5 Years of Follow-Up, Ibrutinib Continues to Impress in CLL/SLL
Ibrutinib showed an 89% response rate in both treatment-naïve and relapsed patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in findings from the longest follow-up to date for the BTK inhibitor.
Lenalidomide Maintenance Improves PFS in High-Risk CLL
Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia.
Lirilumab/Azacytidine Combo Safe, Active in AML
The combination of the killer-cell immunoglobulin-like receptors inhibitor lirilumab with the hypomethylating agent azacytidine was well tolerated and showed early signals of activity in heavily pretreated patients with acute myeloid leukemia.
Enasidenib Shows Promising Activity for IDH2-Mutant MDS
Treatment with enasidenib was active and was well tolerated in pretreated patients with
-mutated myelodysplastic syndrome, including those who failed hypomethylating agents.
Rituximab Maintenance Prolongs Survival in Younger MCL Patients
Younger patients with mantle cell lymphoma lived significantly longer and without disease progression or clinical events when they received rituximab maintenance therapy after stem cell transplantation, final results of a randomized trial showed.
Vadastuximab Talirine Yields Rapid and Deep Remissions in Early Study of Patients With AML
Researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for patients with acute myeloid leukemia.
CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated
The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
TKI Cessation Strategies Emerging for CML
TKIs can safely be stopped or dose-reduced without jeopardizing long-term outcomes for select patients with chronic myeloid leukemia who have obtained a major molecular response.
Impressive Brentuximab Vedotin Data May Change Practice in CTCL
Brentuximab vedotin induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician’s choice of standard therapies, according to findings from the phase III ALCANZA trial presented at the 2016 ASH Annual Meeting.
Survival Improves When Older Patients With AML Receive CPX-351 Before Transplant
CPX-351 may provide a bridge to successful transplantation for older patients with acute myeloid leukemia with limited treatment options.
Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL
Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.
Acalabrutinib Monotherapy Effective for Richter Transformation
The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.
Nivolumab/Ibrutinib Combo Shows Promise for Richter Transformation
Treatment with the combination of nivolumab and ibrutinib showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.
CAR T-Cell Therapy in DLBCL: Centers of Excellence
Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG
Harvard Expert Sees Potential in BCL-2 Combos
Tocilizumab Resolves CRS in Pediatric B-ALL Without Reducing Tisagenlecleucel Efficacy
Bounty of Novel Drugs Ushers In New Era for ALK-Positive NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.